YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Stock market activity shows price changes and trading movements in real time] FabrikaCr Stock futures edged lower in the premarket hours of Thursday as prospects for a diplomatic resolution between the United States and Iran dimmed, while…
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targ…
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate,…
In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 had its…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (NYSE:PFE) and Valneva had their Marketing Authorization Application for a Lyme disease va…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a m…
VALNEVA SE Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the Eur…
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that t…
* Valneva press release [https://seekingalpha.com/pr/20617691-valneva-reports-half-year-2026-financial-results-and-provides-corporate-updates] (VALN [https://seekingalpha.com/symbol/VALN]): 1H GAAP EPS of -€0.35. * Revenue of €65.84M (-32.…
VALNEVA SE Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from…
Le Dr Gerd Zettlmeissl est nommé président du conseil d’administration Lyon (France), le 25 juin 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que toutes les résolutions…
Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that shareholders approved all resolutions rec…
Lyon (France), le 4 juin 2026 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins (« la Société »), a annoncé aujourd’hui la mise à disposition de la documentation relative à son Assemblée Générale ann…
Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting”) to be held on June…
VALNEVA Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences…
On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog,…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
VALNEVA Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 20261 Program launched in April to further reduce operating expenses…
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.…
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.…
Valneva SE (NASDAQ:VALN) is one of the most undervalued biotech stocks to buy right now. Guggenheim cut the price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on April 16, reiterating a Buy rating on the shares. The firm adjusted est…
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.…
Valneva SE (NASDAQ:VALN) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3 V…
Pfizer Inc. (NYSE:PFE) is included among the 15 Large Cap Stocks with Highest Dividends.Pfizer (PFE) - Among the 15 Large Cap Stocks with Highest Dividends Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and…
[Stock Market Ticker Display] bymuratdeniz Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - MARCH 3…
In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine achieved roughly three‑quarters efficacy in a Phase 3 trial, while separate late‑stage studies in prostate and breast ca…
Pfizer Inc. (NYSE:PFE) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In.Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data On March 24, Guggenheim Partners raised its price recomme…
Shares of Valneva VALN tanked 37% on Monday after the company reported top-line results from the phase III VALOR study, which evaluated its experimental Lyme disease vaccine, PF-07307405 (formerly VLA15). The vaccine is being developed in…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over 7…
An experimental Lyme disease vaccine from Pfizer and Valneva didn’t conclusively succeed in a large study, raising questions about the shot’s prospects. While the shot was more than 70% effective at preventing the tick-borne disease in the…
Lyme disease is the most common illness transmitted by ticks (BERTRAND GUAY)·BERTRAND GUAY/AFP/AFP An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday, however the lat…
(RTTNews) - Valneva SE (VALN) saw its stock drop sharply, even as the company and partner Pfizer announced that their Lyme disease vaccine candidate demonstrated more than 70% efficacy in a large Phase 3 study. Lyme disease, spread through…
US equity futures were up ahead of Monday's opening bell after President Donald Trump said he has or PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus.Le candidat vaccin a été bien toléré, sans problème de sécurité identifié…
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease. Continue Reading
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated with no safety concerns identified at tim…